

Checklist for Reporting Human Islet Preparations Used in Research

Manuscript DOI: DB20-0204	
Title: Epigenetic changes in Langerhans islets preceding the onset of diabetes	
Author list: Meriem Ouni, PhD, Sophie Saussenthaler, MSc*, Fabian Eichelmann, PhD*, Markus Jähnert, MSc, Clemens Wittenbecher PhD, Tina Rönn PhD, Lisa Zellner, MSc, Pascal Gottmann, PhD, Charlotte Ling, PhD, Matthias B. Schulze, DrPH and Annette Schürmann, PhD	
Corresponding author: Prof. Dr. Annette Schürmann	Email address: schuermann@dife.de

Islet preparation	1	2	3	4	5	6	7	8 ^a
MANDATORY INFORMATION								
Unique identifier	17	18	19	20	21	22	23	24
Donor age (years)	41	74	46	68	54	56	62	75
Donor sex (M/F)	Male	Male	Female	Female	Male	Female	Male	Female
Donor BMI (kg/m ²)	22.5	23	22.9	21.5	23.4	28	24.8	33.1

Donor HbA _{1c} or other measure of blood glucose control	51	44	31	33	34	38		51
Origin/source of islets ^b	The Nordic Network For Clinical Islet Transplantation							
Islet isolation centre	Uppsala							
Donor history of diabetes? Yes/No	yes	yes	no	no	no	no	yes	yes
If Yes, complete the next two lines if this information is available								
Diabetes duration (years)								
Glucose-lowering therapy at time of death ^c								

RECOMMENDED INFORMATION								
Donor cause of death								
Warm ischaemia time (h)								
Cold ischaemia time (h)								

Estimated purity (%)								
Estimated viability (%)								
Total culture time (h) ^d								
Glucose-stimulated insulin secretion or other functional measurement ^e								
Handpicked to purity? Yes/No								
Additional notes								

^aIf you have used more than eight islet preparations, please complete additional forms as necessary

^bFor example, IIDP, ECIT, Alberta IsletCore

^cPlease specify the therapy/therapies

^dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

^ePlease specify the test and the results